Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07419841 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of the Safety and Tolerability of CTX-10726
A Phase 1 study, sponsored by Compass Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT07419841 is a Phase 1 study that is actively recruiting participants, run by Compass Therapeutics. The registered enrollment target is 70 participants.
The verdict
NCT07419841, a Phase 1 study, is actively recruiting participants, sponsored by Compass Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.
Interventions
- DRUG CTX-10726
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2028-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07419841
The ClinicalTrials.gov registry entry for NCT07419841 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Compass Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CTX-10726 is the first listed.
NCT07419841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07419841 about?
NCT07419841 is a clinical study titled "A Phase 1 Study of the Safety and Tolerability of CTX-10726". This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.
What is the current status of trial NCT07419841?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2026-05-28. Estimated completion is 2028-11-01.
What interventions are being tested in trial NCT07419841?
The interventions under investigation include: CTX-10726 (DRUG).
Who is sponsoring clinical trial NCT07419841?
This trial is sponsored by Compass Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.